亚洲最大赌博网站

Guantao Law Firm helped Proteint (Tianjin) Biotech Co., Ltd. get the exclusive Series A funding from CDH Baifu

Proteint (Tianjin) Biotech Co., Ltd. (“Proteint”) got nearly 100 million yuan in the Series A investment, which was exclusively invested by the leading company CDH Baifu. The Tianjin Office of Guantao Law Firm worked as the legal adviser for this project with legal service throughout the process. 

Proteint is one the first High-tech companies introducing multiple omics technology in clinical use. With a focus on clinical needs, it brings proteomics and metabolomics on top of genomics, tackling the weakness of genomics alone with holistic and systematic research on “genes, proteins and metabolism”. It can provide more precise and even personalized clinical solutions. To date, Proteint has quality control capacity in the entire process and IP deployment covering seven areas, including sample preparation, auxiliary materials, mass spectrometry, data analysis, clinical use, etc. 

CDH Baifu, a leading institution in China, will use its strengths in biomedicine to empower Proteint, accelerate the clinical use of innovative technology, facilitate the clinical use of multiple omics and improve the development of precise medicine in China.

The Tianjin Office of Guantao Law Firm worked as the legal adviser and helped Proteint complete this financing project. The legal service covered the entire financing process, including the drafting, reviewing, and modifying of the transaction documents, participating in negotiations, and assisting in the project delivery. This project was led by attorney SONG Liang, partner of Guantao Law Firm, and supported by attorney YIN Weiqi and attorney ZHAO Shuyi.